



**Nearly 7 billion**  
**patient treatment days**  
with EU  
approved biosimilar  
medicines since 2006



**The number of treatment**  
**days** with anti-TNF  
medicines  
**has doubled**  
from 2013-2023



**€56 billion**  
**cumulative savings**  
from the impact of biosimilar  
competition since 2006,  
**€6 billion**  
in 2024 alone



A growing opportunity  
for patients with over  
**110 new biologic**  
**medicines** opening to  
biosimilar competition  
by 2032



A considerable  
opportunity for European  
healthcare  
market will **open to**  
**competition**  
budget: **€53.5Bn**



By 2030,  
**1st cell & gene**  
**therapies** will open to  
biosimilar competition



Biosimilar medicines  
opportunity remains  
largely untapped with only  
**12 % volume share**  
of the accessible market  
in Europe



Biosimilar medicines  
represent **4%** of the  
**total pharmaceutical**  
**spending** in Europe  
(<€10 billion)

**Nearly 7 billion**  
**patient treatment days**  
with EU approved  
biosimilar medicines  
since 2006



Thanks to biosimilar competition, **the number of treatment days** with anti- TNF medicines **has doubled** from 2013-2023



**€56 billion**  
**cumulative savings**  
from the impact of biosimilar  
competition since 2006,  
**€6 billion**  
in 2024 alone



A growing opportunity  
for patients with over  
**110 new biologic  
medicines** opening to  
biosimilar competition  
by 2032



A considerable opportunity  
for European healthcare  
budget: a **€53.5Bn**  
market will **open to**  
**competition** by 2032  
peaking at **€30Bn**  
between 2030-2032




By 2030,  
**1st cell & gene  
therapies** will open to  
biosimilar competition




Biosimilar medicines  
opportunity remains largely  
untapped with only

**12% volume share**  
of the accessible market  
in Europe





Biosimilar medicines  
represent **4%** of the  
**total pharmaceutical  
spending** in Europe  
(<€10 billion)



**Biosimilar candidates**  
are under development for  
**1/3 of biologics** losing  
exclusivity by 2032

